The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome p-450 isozymes catalysing bufuralol and mephenytoin oxidation

U. A. Meyer, J. Gut, T. Kronbach, C. Skoda, U. Thomas Meier, T. Catin, P. Dayer

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

1. Using the stereospecific metabolism of (+and (-bufuralol and (+ and (-metoprolol as model reactions, we have characterized the enzymic deficiency of the debrisoquine/sparteine-type polymorphism by comparing kinetic data of subjects in vivo with their microsomal activities in vitro and with reconstituted activities of cytochrome P-450 isozymes purified from human liver. 2. The metabolism of bufuralol in liver microsomes of in vivo phenotyped 'poor metabolizers' of debrisoquine and/or sparteine is characterized by a marked increase in Km, a decrease in Vmax and a virtual loss of the stereoselectivity of the reaction. These parameters apparently allow the 'phenotyping' of microsomes in vitro. 3. A structural model of the active site of a cytochrome P-450 for stereospecific metabolism of bufuralol and other polymorphically metabolized substrates was constructed. 4. Two cytochrome P-450 isozymes, P-450 buf I and P-450 buf II, both with MW 50 000 Da, were purified from human liver on the basis of their ability to metabolize bufuralol to 1'hydroxy-bufuralol. However, P-450 buf I metabolized bufuralol in a highly stereoselective fashion ((-plus; ratio 0·16) as compared to P-450 buf II (ratio 0·99) and had a markedly lower Km for bufuralol. Moreover, bufuralol 1'hydroxylation by P-450 buf I was uniquely characterized by its extreme sensitivity to inhibition by quinidine. 5. Antibodies against P-450 buf I and P-450 buf II inhibited bufuralol metabolism in microsomes and with the reconstituted enzymes. Immunochemical studies with these antibodies with microsomes and translations in vitro of RNA from livers of extensive and poor metabolizers showed no evidence for a decrease in the recognized protein or its mRNA. Because the antibodies do not discriminate between P-450 buf I and P-450 buf II, both a decreased content of P-450 buf I or its functional alteration could explain the polymorphic metabolism in microsomes. 6. The genetically defective stereospecific metabolism of mephenytoin was determined in liver microsomes of extensive and poor metabolizers of mephenytoin phenotyped in vivo. Microsomes of poor metabolizers were characterized by an increased Km and a decreased Vmax for S-mephenytoin hydroxylation as compared to extensive metabolizers and a loss of stereospecificity for the hydroxylation of S-versus R-mephenytoin. A cytochrome P-450 with high activity for mephenytoin 4-hydroxylation was purified from human liver. Immunochemical studies with inhibitory antibodies against this isozyme suggest the presence in poor-metabolizer microsomes of a functionally altered enzyme.

Original languageEnglish (US)
Pages (from-to)449-464
Number of pages16
JournalXenobiotica
Volume16
Issue number5
DOIs
StatePublished - Jan 1 1986
Externally publishedYes

Fingerprint

Mephenytoin
Cytochromes
Polymorphism
Isoenzymes
Microsomes
Metabolism
Liver
Oxidation
Hydroxylation
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System
Sparteine
Debrisoquin
Antibodies
Liver Microsomes
bufuralol
Stereoselectivity
Metoprolol
Quinidine
Structural Models

ASJC Scopus subject areas

  • Biochemistry
  • Toxicology
  • Pharmacology
  • Health, Toxicology and Mutagenesis

Cite this

The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome p-450 isozymes catalysing bufuralol and mephenytoin oxidation. / Meyer, U. A.; Gut, J.; Kronbach, T.; Skoda, C.; Meier, U. Thomas; Catin, T.; Dayer, P.

In: Xenobiotica, Vol. 16, No. 5, 01.01.1986, p. 449-464.

Research output: Contribution to journalArticle

@article{a4e2644a0dd14a3b9c04a673fd09586f,
title = "The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome p-450 isozymes catalysing bufuralol and mephenytoin oxidation",
abstract = "1. Using the stereospecific metabolism of (+and (-bufuralol and (+ and (-metoprolol as model reactions, we have characterized the enzymic deficiency of the debrisoquine/sparteine-type polymorphism by comparing kinetic data of subjects in vivo with their microsomal activities in vitro and with reconstituted activities of cytochrome P-450 isozymes purified from human liver. 2. The metabolism of bufuralol in liver microsomes of in vivo phenotyped 'poor metabolizers' of debrisoquine and/or sparteine is characterized by a marked increase in Km, a decrease in Vmax and a virtual loss of the stereoselectivity of the reaction. These parameters apparently allow the 'phenotyping' of microsomes in vitro. 3. A structural model of the active site of a cytochrome P-450 for stereospecific metabolism of bufuralol and other polymorphically metabolized substrates was constructed. 4. Two cytochrome P-450 isozymes, P-450 buf I and P-450 buf II, both with MW 50 000 Da, were purified from human liver on the basis of their ability to metabolize bufuralol to 1'hydroxy-bufuralol. However, P-450 buf I metabolized bufuralol in a highly stereoselective fashion ((-plus; ratio 0·16) as compared to P-450 buf II (ratio 0·99) and had a markedly lower Km for bufuralol. Moreover, bufuralol 1'hydroxylation by P-450 buf I was uniquely characterized by its extreme sensitivity to inhibition by quinidine. 5. Antibodies against P-450 buf I and P-450 buf II inhibited bufuralol metabolism in microsomes and with the reconstituted enzymes. Immunochemical studies with these antibodies with microsomes and translations in vitro of RNA from livers of extensive and poor metabolizers showed no evidence for a decrease in the recognized protein or its mRNA. Because the antibodies do not discriminate between P-450 buf I and P-450 buf II, both a decreased content of P-450 buf I or its functional alteration could explain the polymorphic metabolism in microsomes. 6. The genetically defective stereospecific metabolism of mephenytoin was determined in liver microsomes of extensive and poor metabolizers of mephenytoin phenotyped in vivo. Microsomes of poor metabolizers were characterized by an increased Km and a decreased Vmax for S-mephenytoin hydroxylation as compared to extensive metabolizers and a loss of stereospecificity for the hydroxylation of S-versus R-mephenytoin. A cytochrome P-450 with high activity for mephenytoin 4-hydroxylation was purified from human liver. Immunochemical studies with inhibitory antibodies against this isozyme suggest the presence in poor-metabolizer microsomes of a functionally altered enzyme.",
author = "Meyer, {U. A.} and J. Gut and T. Kronbach and C. Skoda and Meier, {U. Thomas} and T. Catin and P. Dayer",
year = "1986",
month = "1",
day = "1",
doi = "10.3109/00498258609050251",
language = "English (US)",
volume = "16",
pages = "449--464",
journal = "Xenobiotica",
issn = "0049-8254",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome p-450 isozymes catalysing bufuralol and mephenytoin oxidation

AU - Meyer, U. A.

AU - Gut, J.

AU - Kronbach, T.

AU - Skoda, C.

AU - Meier, U. Thomas

AU - Catin, T.

AU - Dayer, P.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - 1. Using the stereospecific metabolism of (+and (-bufuralol and (+ and (-metoprolol as model reactions, we have characterized the enzymic deficiency of the debrisoquine/sparteine-type polymorphism by comparing kinetic data of subjects in vivo with their microsomal activities in vitro and with reconstituted activities of cytochrome P-450 isozymes purified from human liver. 2. The metabolism of bufuralol in liver microsomes of in vivo phenotyped 'poor metabolizers' of debrisoquine and/or sparteine is characterized by a marked increase in Km, a decrease in Vmax and a virtual loss of the stereoselectivity of the reaction. These parameters apparently allow the 'phenotyping' of microsomes in vitro. 3. A structural model of the active site of a cytochrome P-450 for stereospecific metabolism of bufuralol and other polymorphically metabolized substrates was constructed. 4. Two cytochrome P-450 isozymes, P-450 buf I and P-450 buf II, both with MW 50 000 Da, were purified from human liver on the basis of their ability to metabolize bufuralol to 1'hydroxy-bufuralol. However, P-450 buf I metabolized bufuralol in a highly stereoselective fashion ((-plus; ratio 0·16) as compared to P-450 buf II (ratio 0·99) and had a markedly lower Km for bufuralol. Moreover, bufuralol 1'hydroxylation by P-450 buf I was uniquely characterized by its extreme sensitivity to inhibition by quinidine. 5. Antibodies against P-450 buf I and P-450 buf II inhibited bufuralol metabolism in microsomes and with the reconstituted enzymes. Immunochemical studies with these antibodies with microsomes and translations in vitro of RNA from livers of extensive and poor metabolizers showed no evidence for a decrease in the recognized protein or its mRNA. Because the antibodies do not discriminate between P-450 buf I and P-450 buf II, both a decreased content of P-450 buf I or its functional alteration could explain the polymorphic metabolism in microsomes. 6. The genetically defective stereospecific metabolism of mephenytoin was determined in liver microsomes of extensive and poor metabolizers of mephenytoin phenotyped in vivo. Microsomes of poor metabolizers were characterized by an increased Km and a decreased Vmax for S-mephenytoin hydroxylation as compared to extensive metabolizers and a loss of stereospecificity for the hydroxylation of S-versus R-mephenytoin. A cytochrome P-450 with high activity for mephenytoin 4-hydroxylation was purified from human liver. Immunochemical studies with inhibitory antibodies against this isozyme suggest the presence in poor-metabolizer microsomes of a functionally altered enzyme.

AB - 1. Using the stereospecific metabolism of (+and (-bufuralol and (+ and (-metoprolol as model reactions, we have characterized the enzymic deficiency of the debrisoquine/sparteine-type polymorphism by comparing kinetic data of subjects in vivo with their microsomal activities in vitro and with reconstituted activities of cytochrome P-450 isozymes purified from human liver. 2. The metabolism of bufuralol in liver microsomes of in vivo phenotyped 'poor metabolizers' of debrisoquine and/or sparteine is characterized by a marked increase in Km, a decrease in Vmax and a virtual loss of the stereoselectivity of the reaction. These parameters apparently allow the 'phenotyping' of microsomes in vitro. 3. A structural model of the active site of a cytochrome P-450 for stereospecific metabolism of bufuralol and other polymorphically metabolized substrates was constructed. 4. Two cytochrome P-450 isozymes, P-450 buf I and P-450 buf II, both with MW 50 000 Da, were purified from human liver on the basis of their ability to metabolize bufuralol to 1'hydroxy-bufuralol. However, P-450 buf I metabolized bufuralol in a highly stereoselective fashion ((-plus; ratio 0·16) as compared to P-450 buf II (ratio 0·99) and had a markedly lower Km for bufuralol. Moreover, bufuralol 1'hydroxylation by P-450 buf I was uniquely characterized by its extreme sensitivity to inhibition by quinidine. 5. Antibodies against P-450 buf I and P-450 buf II inhibited bufuralol metabolism in microsomes and with the reconstituted enzymes. Immunochemical studies with these antibodies with microsomes and translations in vitro of RNA from livers of extensive and poor metabolizers showed no evidence for a decrease in the recognized protein or its mRNA. Because the antibodies do not discriminate between P-450 buf I and P-450 buf II, both a decreased content of P-450 buf I or its functional alteration could explain the polymorphic metabolism in microsomes. 6. The genetically defective stereospecific metabolism of mephenytoin was determined in liver microsomes of extensive and poor metabolizers of mephenytoin phenotyped in vivo. Microsomes of poor metabolizers were characterized by an increased Km and a decreased Vmax for S-mephenytoin hydroxylation as compared to extensive metabolizers and a loss of stereospecificity for the hydroxylation of S-versus R-mephenytoin. A cytochrome P-450 with high activity for mephenytoin 4-hydroxylation was purified from human liver. Immunochemical studies with inhibitory antibodies against this isozyme suggest the presence in poor-metabolizer microsomes of a functionally altered enzyme.

UR - http://www.scopus.com/inward/record.url?scp=0022899555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022899555&partnerID=8YFLogxK

U2 - 10.3109/00498258609050251

DO - 10.3109/00498258609050251

M3 - Article

VL - 16

SP - 449

EP - 464

JO - Xenobiotica

JF - Xenobiotica

SN - 0049-8254

IS - 5

ER -